Ponatinib (AP24534)

Name: Ponatinib (AP24534)
Brand: Selleck Chemicals
SKU: S1490
Rating: 5 (95 reviews)

For research use only.

Catalog No.S1490

95 publications

Molecular Weight(MW): 532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively. Ponatinib (AP24534) inhibits autophagy.

Selleck's Ponatinib (AP24534) has been cited by 95 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.32924

PubMed: 32064608 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

J Infect Dis, 2020, 3;jiaa295

PubMed: 32492702 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 30;11:543

PubMed: 32425788 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020, 1;6(2) pii: a004838

PubMed: 31980503 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )
Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )
Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Blood, 2016, 28;127(17):2131-43

PubMed: 26864341 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )
Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NGG0N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvVTWM2OD1yLkCwNFAxODB\|NUmg{txO	NWnhWGdKW0GQR1XS
MV-4-11	NF:yZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rTSWlEPTB;MD6wNFAxQTV4IN88US=>	MU\TRW5ITVJ?
MEG-01	NHfV[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrON2lKSzVyPUCuNFAxOTJ6IN88US=>	NYPlOHhYW0GQR1XS
LAMA-84	NWHtN5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHlOFk{UUN3ME2wMlAxODF4NTFOwG0>	MkH3V2FPT0WU
CGTH-W-1	NWXFbWpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfrZ4lKSzVyPUCuNFAyPjlizszN	NVjTU2w3W0GQR1XS
KASUMI-1	NXzSdmk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f5fWlEPTB;MD6wNFIyPyEQvF2=	NHr2bYJUSU6JRWK=
BE-13	NF\x[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLKTWM2OD1yLkCwNlU6KM7:TR?=	NFvDOnpUSU6JRWK=
CTV-1	M1HPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fOWGlEPTB;MD6wNFUzOSEQvF2=	M3vMSXNCVkeHUh?=
NKM-1	M3jWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEC2OVUh\|ryP	NFiwZnBUSU6JRWK=
MONO-MAC-6	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHIc4pKSzVyPUCuNFA5OzdizszN	M{XaUXNCVkeHUh?=
A204	NV\NN2VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDTTWM2OD1yLkCxNlE5KM7:TR?=	Mkj2V2FPT0WU
GDM-1	NFr4fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMEG4N\|Mh\|ryP	Mn7ZV2FPT0WU
AN3-CA	M4rJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWSzS4RDUUN3ME2wMlAyQDd\|IN88US=>	NYCwVWxwW0GQR1XS
BL-70	NIjLNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEKxPVkh\|ryP	MUDTRW5ITVJ?
Daudi	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jLcWlEPTB;MD6wNlU{PyEQvF2=	NV3RZnpQW0GQR1XS
KU812	M{P1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEK4OFgh\|ryP	NGTufZBUSU6JRWK=
KG-1	NFnZOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDpWlZKSzVyPUCuNFMzQTRizszN	M1nxfXNCVkeHUh?=
DOHH-2	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMES4NFMh\|ryP	NEXmS5pUSU6JRWK=
HuO9	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHySVBmUUN3ME2wMlA2PDR6IN88US=>	MlXDV2FPT0WU
EB2	NHnteGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3ZV21KSzVyPUCuNFU2PzZizszN	NIO0bplUSU6JRWK=
G-402	NFzU[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HjZ2lEPTB;MD6wOlM1OSEQvF2=	MkDpV2FPT0WU
SU-DHL-1	NIOycnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHO4[ohKSzVyPUCuNFY{PzlizszN	MV7TRW5ITVJ?
NCI-H719	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnR[YF4UUN3ME2wMlA4QDh6IN88US=>	MoKwV2FPT0WU
MLMA	M17CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFu3bHdKSzVyPUCuNFkxPiEQvF2=	NXf1RWFIW0GQR1XS
KM12	M{O5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PSO2lEPTB;MD6wPVc{PyEQvF2=	M{fTVHNCVkeHUh?=
SUP-T1	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\HTIl5UUN3ME2wMlA6QTh{IN88US=>	NUfvPVBpW0GQR1XS
MZ1-PC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vBWWlEPTB;MD6xNVM{PiEQvF2=	MWLTRW5ITVJ?
MFE-296	NGXSZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLCTWM2OD1yLkGxPFM6KM7:TR?=	MnTOV2FPT0WU
ALL-PO	NVu5epE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfDeI5KSzVyPUCuNVI1PDNizszN	NUHwO\|E6W0GQR1XS
GB-1	NXHVfWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTv[IJGUUN3ME2wMlEzPTF{IN88US=>	NV21WVZHW0GQR1XS
SIG-M5	NVfidm1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq3RmZjUUN3ME2wMlE{OzdizszN	MoPVV2FPT0WU
P30-OHK	NHrsZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDnWmJKSzVyPUCuNVU3PzJizszN	MX;TRW5ITVJ?
NCI-H716	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v6b2lEPTB;MD6xOlI3PiEQvF2=	M4G0ZnNCVkeHUh?=
MPP-89	NH7lZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPCVGZKSzVyPUCuNVY6OzNizszN	MXvTRW5ITVJ?
SF126	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvTbId[UUN3ME2wMlE4ODZ\|IN88US=>	M4TWZ3NCVkeHUh?=
CTB-1	NEi5dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMUezNVYh\|ryP	M4rKPXNCVkeHUh?=
CA46	M3PoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;wW3ZRUUN3ME2wMlE4PDh7IN88US=>	MkLGV2FPT0WU
NCI-H520	NHHO[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHXSnlKSzVyPUCuNVc4OzJizszN	M2PaW3NCVkeHUh?=
CAL-85-1	NXLxWGdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMUe5Nlch\|ryP	NHPRUGlUSU6JRWK=
NCI-H2342	M3u5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMUi1O\|ch\|ryP	MX3TRW5ITVJ?
697	M3H5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMUi4O\|Eh\|ryP	NFe5NlJUSU6JRWK=
NY	Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\sTWM2OD1yLkG5Nlg4KM7:TR?=	M2e4NHNCVkeHUh?=
T98G	Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPzWmxKSzVyPUCuNVk{OThizszN	M1m3WHNCVkeHUh?=
NCI-H1703	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3JTWM2OD1yLkG5OlE2KM7:TR?=	M{L3U3NCVkeHUh?=
NCI-H2087	NFnvZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7HVGNKSzVyPUCuNlA1OzlizszN	NWfyU5hCW0GQR1XS
PF-382	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jD[2lEPTB;MD6yNFg4OyEQvF2=	M3nTNnNCVkeHUh?=
HCT-116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;4e2lEPTB;MD6yNVA3QSEQvF2=	MXTTRW5ITVJ?
CAKI-1	NWrzT\|loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFH4bnBKSzVyPUCuNlE3PjZizszN	MW\TRW5ITVJ?
CCF-STTG1	NEjybFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMkK0O\|Uh\|ryP	NITQW3VUSU6JRWK=
D-392MG	NH\pbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMkOxO\|ch\|ryP	MlnFV2FPT0WU
RT-112	NWXoV4Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Ky[2lEPTB;MD6yN\|c6PSEQvF2=	NF;S[FdUSU6JRWK=
MES-SA	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;SWGlEPTB;MD6yOFE5PyEQvF2=	NWnIbllGW0GQR1XS
LC-2-ad	NHzHeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;yTWM2OD1yLkK0NlY2KM7:TR?=	MW\TRW5ITVJ?
NOS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMkSzOlch\|ryP	NHTUN5RUSU6JRWK=
NALM-6	NH3ZZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMkW1OFMh\|ryP	NEPOeHNUSU6JRWK=
TE-15	NX3B[2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVm1eYhHUUN3ME2wMlI3ODlzIN88US=>	MYPTRW5ITVJ?
786-0	M{jVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMk[yNlgh\|ryP	NI\aXnVUSU6JRWK=
IST-MES1	M2XCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnUdY9KSzVyPUCuNlY5OjlizszN	MUnTRW5ITVJ?
KYSE-180	NVzCfVdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHnNppKSzVyPUCuNlY5QTFizszN	NX3MUG9SW0GQR1XS
YT	MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvmTWM2OD1yLkK2PVc1KM7:TR?=	MXvTRW5ITVJ?
A427	NVniVVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVThN3A3UUN3ME2wMlI4OjZ2IN88US=>	MUfTRW5ITVJ?
KYSE-450	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\GbGtCUUN3ME2wMlI4OzJ7IN88US=>	MlfBV2FPT0WU
HuH-7	M4nqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\ST2RKSzVyPUCuNlc4PjNizszN	MUXTRW5ITVJ?
CAS-1	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fjXGlEPTB;MD6yPFMxOyEQvF2=	MULTRW5ITVJ?
KURAMOCHI	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlX6TWM2OD1yLkK4OFE6KM7:TR?=	M3\BdHNCVkeHUh?=
ACHN	NV;5U21zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrLbFdKSzVyPUCuNlk{OjNizszN	Ml7vV2FPT0WU
HGC-27	NIWxcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[yV2lEPTB;MD6yPVM2OyEQvF2=	MVjTRW5ITVJ?
A172	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{G1[2lEPTB;MD6yPVU4PyEQvF2=	NH\4eGdUSU6JRWK=
SNU-449	NVfCOlRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorzTWM2OD1yLkK5PVY1KM7:TR?=	M4TTfHNCVkeHUh?=
SW982	NI\6cnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWraR5p{UUN3ME2wMlI6QTd6IN88US=>	MlPTV2FPT0WU
EFO-21	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3sWldKSzVyPUCuN\|A1OTFizszN	MWPTRW5ITVJ?
NCI-H2030	M3[3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDpTWM2OD1yLkOxNVY1KM7:TR?=	MmnlV2FPT0WU
HT-144	Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjkTWM2OD1yLkOxNlgh\|ryP	M1j3VnNCVkeHUh?=
MFE-280	NVj5NmhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwM{G0OVMh\|ryP	NITvV4pUSU6JRWK=
SK-LU-1	M1HRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PpZmlEPTB;MD6zNVQ3PiEQvF2=	NHjEeIlUSU6JRWK=
NCI-H2052	NXmzd2N3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHWTWM2OD1yLkOxOFg1KM7:TR?=	MVLTRW5ITVJ?
SK-HEP-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTRTWM2OD1yLkOzN\|Y5KM7:TR?=	MUPTRW5ITVJ?
QIMR-WIL	NVSxWo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkH2TWM2OD1yLkOzOFI1KM7:TR?=	NEHie5NUSU6JRWK=
A2780	NX\xOoFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXwd3lYUUN3ME2wMlM1OzB2IN88US=>	NFf3W5BUSU6JRWK=
ACN	NGLjWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfNWFhCUUN3ME2wMlM1QDd\|IN88US=>	M4P6XnNCVkeHUh?=
BxPC-3	NYXWRld2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\YU2lEPTB;MD6zOFk5QSEQvF2=	MWPTRW5ITVJ?
BCPAP	NVHTcG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjVUZdKSzVyPUCuN\|YxODFizszN	NFThR4hUSU6JRWK=
HOP-62	NVjidIduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrlZZZKSzVyPUCuN\|YyODZizszN	MVrTRW5ITVJ?
SW1710	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3sb2lyUUN3ME2wMlM3PDV3IN88US=>	MnzUV2FPT0WU
OPM-2	NYnWOWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo[3TWM2OD1yLkO2OFc{KM7:TR?=	M1q2SHNCVkeHUh?=
DBTRG-05MG	NXf6W2x6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL2OGRYUUN3ME2wMlM5ODV2IN88US=>	M2j6Z3NCVkeHUh?=
SK-MEL-24	NYXNeZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LlUmlEPTB;MD6zPVc6OSEQvF2=	M4jpb3NCVkeHUh?=
8305C	NWLOeYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4GzW2lEPTB;MD6zPVc6OyEQvF2=	MYfTRW5ITVJ?
OVCAR-4	NVOwelVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S2RWlEPTB;MD60NVU5PiEQvF2=	Ml7SV2FPT0WU
HLE	MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\GcFdKSzVyPUCuOFE5PiEQvF2=	M3;a[3NCVkeHUh?=
NCI-H747	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPqVI1JUUN3ME2wMlQzOTN5IN88US=>	NXL4ZXY5W0GQR1XS
SW780	NUOyT5JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXUZlhoUUN3ME2wMlQzOzR4IN88US=>	NInRPZFUSU6JRWK=
KYSE-150	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDSXndKSzVyPUCuOFI1OTVizszN	MV;TRW5ITVJ?
H4	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYT4W3Z4UUN3ME2wMlQzPDVzIN88US=>	M2PpcXNCVkeHUh?=
SW1088	Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjNWlJKSzVyPUCuOFQ{QSEQvF2=	MnGxV2FPT0WU
SF268	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULkR2ZmUUN3ME2wMlQ1QDZizszN	NWDVW3JKW0GQR1XS
RT4	NV[wWlFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXuTWM2OD1yLkS1NVEyKM7:TR?=	M4LibHNCVkeHUh?=
NCI-H522	M{\lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PmV2lEPTB;MD60OVI4KM7:TR?=	MlmyV2FPT0WU
LCLC-97TM1	NYTHc2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwNE[xPVUh\|ryP	M{HObHNCVkeHUh?=
CAL-39	NGTWeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M173UGlEPTB;MD60OlUyQSEQvF2=	MlvmV2FPT0WU
CAL-120	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDNdIxKSzVyPUCuOFc3PDNizszN	NYTDSJZ1W0GQR1XS
ESS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLGTWM2OD1yLkS3PFIyKM7:TR?=	MnXDV2FPT0WU
KARPAS-45	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwNEi5N\|Mh\|ryP	M3\iSXNCVkeHUh?=
DU-4475	M{i5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zqfWlEPTB;MD60PVUyOSEQvF2=	MkToV2FPT0WU
VMRC-RCZ	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLKZnVyUUN3ME2wMlQ6QTB2IN88US=>	NVHjc4xDW0GQR1XS
HOS	NVn5XYRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPUdVNIUUN3ME2wMlUxOzZ3IN88US=>	M4rXNnNCVkeHUh?=
MOLT-16	NHLDN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwNUG4NFgh\|ryP	MXXTRW5ITVJ?
RPMI-6666	M1fhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUSzVVI2UUN3ME2wMlUzOTN3IN88US=>	NIO4UYNUSU6JRWK=
K052	NEi0SHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHo[W57UUN3ME2wMlUzOTRizszN	NX;vbo5WW0GQR1XS
EHEB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNUKxPFIh\|ryP	NInue3BUSU6JRWK=
MFH-ino	NEnlZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\pbI1UUUN3ME2wMlUzOzVzIN88US=>	MVXTRW5ITVJ?
A4-Fuk	M1PaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwNUK1Nlgh\|ryP	MWfTRW5ITVJ?
SW1417	NHe2RWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly5TWM2OD1yLkWyO\|gyKM7:TR?=	NFflUZpUSU6JRWK=
DoTc2-4510	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3zc5NKSzVyPUCuOVQ6PThizszN	NGnQS2ZUSU6JRWK=
TE-12	M3yzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDh[FlKSzVyPUCuOVU4OzVizszN	M4jJcXNCVkeHUh?=
8-MG-BA	NWq1OWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwNU[wOVYh\|ryP	MXrTRW5ITVJ?
ECC12	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3GTWM2OD1yLkW2OVU5KM7:TR?=	NU\TTW1VW0GQR1XS
CHL-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXCVGtKSzVyPUCuOVc1PjNizszN	MUPTRW5ITVJ?
LCLC-103H	M2nub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXNNVV6UUN3ME2wMlU5OzR2IN88US=>	MlO0V2FPT0WU
OS-RC-2	NGC3dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHLTWM2OD1yLkW4N\|c6KM7:TR?=	MlPGV2FPT0WU
RO82-W-1	NEiyeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXtSIFKSzVyPUCuOVk3OTVizszN	NFX5ZmhUSU6JRWK=
A3-KAW	M1\ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\1RmlEPTB;MD62NVQ3PyEQvF2=	MWnTRW5ITVJ?
NCCIT	M{PrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLoTWM2OD1yLk[xO\|E2KM7:TR?=	MmLBV2FPT0WU
IST-SL2	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInyNo9KSzVyPUCuOlI2OjJizszN	MlfhV2FPT0WU
GI-ME-N	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwNkOwOlkh\|ryP	Mly1V2FPT0WU
ES6	MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3nTWM2OD1yLk[zNlk2KM7:TR?=	NVTP[XdMW0GQR1XS
BL-41	NV\nO5V{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnniTWM2OD1yLk[zN\|UzKM7:TR?=	Mn70V2FPT0WU
Ca-Ski	M3HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn30TWM2OD1yLk[0PFEh\|ryP	MV;TRW5ITVJ?
HOP-92	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNkW2O\|Ih\|ryP	NEjEb5lUSU6JRWK=
SK-LMS-1	M1jZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3FTWM2OD1yLk[2OFch\|ryP	M2jJcXNCVkeHUh?=
EW-13	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHsTWM2OD1yLk[2O\|c6KM7:TR?=	MnjBV2FPT0WU
647-V	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2m4O2lEPTB;MD62PFE1QCEQvF2=	NWPxfppUW0GQR1XS
JiyoyeP-2003	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG0PJBKSzVyPUCuOlk4OzhizszN	NVHEUnpWW0GQR1XS
WSU-NHL	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\oTWM2OD1yLkewPFg4KM7:TR?=	NFPNV4pUSU6JRWK=
U-698-M	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEf3OI1KSzVyPUCuO\|ExPjNizszN	NV\U[odQW0GQR1XS
HC-1	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUThWYdMUUN3ME2wMlczPDB3IN88US=>	MlO5V2FPT0WU
8505C	NI\GS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXK4Oo9JUUN3ME2wMlczPzRzIN88US=>	MULTRW5ITVJ?
HUTU-80	NEDYO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYO0RWp[UUN3ME2wMlc{OzR7IN88US=>	NWPaOpBDW0GQR1XS
LB1047-RCC	M4r0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjrTWM2OD1yLkezOVM5KM7:TR?=	MWLTRW5ITVJ?
GAMG	Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnpSXFKSzVyPUCuO\|M3PTNizszN	M176fnNCVkeHUh?=
CAL-12T	NH3sSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwN{O4O\|ch\|ryP	M1TXfXNCVkeHUh?=
NCI-SNU-1	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWqwS3JZUUN3ME2wMlc4Ojd6IN88US=>	MlP1V2FPT0WU
HTC-C3	NYn3N206T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7RR2luUUN3ME2wMlc4PDVzIN88US=>	MlPlV2FPT0WU
HPAF-II	NWrmb\|dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwN{e1NFEh\|ryP	NH7oZmFUSU6JRWK=
KGN	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3yTWM2OD1yLke4NFgyKM7:TR?=	MX3TRW5ITVJ?
EFO-27	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwN{i3N\|Mh\|ryP	MnXqV2FPT0WU
MEL-HO	NGPXN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX1RpZKSzVyPUCuO\|k1PDlizszN	NIrydmRUSU6JRWK=
KYSE-270	NHfRVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVv4[4djUUN3ME2wMlgxPTJ7IN88US=>	Mm\kV2FPT0WU
NCI-H1755	NH\pdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjlSnRnUUN3ME2wMlgxPzF2IN88US=>	MlfzV2FPT0WU
MFM-223	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLBWoNKSzVyPUCuPFE1ODdizszN	M1zYe3NCVkeHUh?=
G-361	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{C3[GlEPTB;MD64NVg6PyEQvF2=	NWi5O2dtW0GQR1XS
ETK-1	M4\0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLlUHZMUUN3ME2wMlgzPDRzIN88US=>	MYHTRW5ITVJ?
LU-99A	MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkG1TWM2OD1yLki0O\|AyKM7:TR?=	NFfoNHZUSU6JRWK=
IST-MEL1	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;HZ2lEPTB;MD64OVc{OiEQvF2=	MYfTRW5ITVJ?
L-540	M37NUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojwTWM2OD1yLki1PFAyKM7:TR?=	NH\W[5VUSU6JRWK=
U-2-OS	NFv0N4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlj2TWM2OD1yLki1PFQ3KM7:TR?=	Mme5V2FPT0WU
HT-1376	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX22fot6UUN3ME2wMlg3ODVzIN88US=>	NH[ySnlUSU6JRWK=
COLO-680N	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1y2bmlEPTB;MD64O\|k{OyEQvF2=	NWLORYxNW0GQR1XS
NCI-H1581	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPQbVhiUUN3ME2wMlg6Ojl5IN88US=>	MWXTRW5ITVJ?
HuCCT1	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;zRmlEPTB;MD64PVU1QCEQvF2=	MVjTRW5ITVJ?
BB30-HNC	NEHUcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXLTWM2OD1yLkmyOFY6KM7:TR?=	MojpV2FPT0WU
NCI-H2347	NV2xcXpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f4dWlEPTB;MD65N\|I6OiEQvF2=	MkXVV2FPT0WU
G-401	M2jDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmmxTWM2OD1yLkmzOlk2KM7:TR?=	MV7TRW5ITVJ?
NCI-H358	NV;0bY1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LMTWlEPTB;MD65OVAyPCEQvF2=	MX\TRW5ITVJ?
HCC1395	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV6xOWFUUUN3ME2wMlk2PDZzIN88US=>	M4riT3NCVkeHUh?=
J82	M{Lxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwOUW1OFMh\|ryP	NUj0e\|J4W0GQR1XS
KE-37	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwOU[zPFch\|ryP	M1nSfHNCVkeHUh?=
NOMO-1	Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHOdoxUUUN3ME2wMlk3PTZ2IN88US=>	MYfTRW5ITVJ?
ML-2	M{G5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwOUm3OUDPxE1?	NVWxXYg2W0GQR1XS
SW872	M2rod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\3XGlEPTB;MD65PVc4PSEQvF2=	MYDTRW5ITVJ?
KYSE-520	NVn1PJA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP1TWM2OD1zLkCwOFk1KM7:TR?=	NHjBPINUSU6JRWK=
HL-60	NV3tZ5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DhRWlEPTB;MT6wNFk4KM7:TR?=	NGq4Z3NUSU6JRWK=
HDLM-2	Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXaTWM2OD1zLkCxNlUzKM7:TR?=	NEDxN\|lUSU6JRWK=
MIA-PaCa-2	NEnST2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7iNVRKSzVyPUGuNFE{PzVizszN	MYnTRW5ITVJ?
TCCSUP	M4Ps[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i5fGlEPTB;MT6wNVc{OiEQvF2=	M2fFU3NCVkeHUh?=
SH-4	MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL6b2l4UUN3ME2xMlAzOjR2IN88US=>	MXzTRW5ITVJ?
MG-63	NV;5eZg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLNTWM2OD1zLkCyOlE3KM7:TR?=	NYfmeHI5W0GQR1XS
NB6	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLMTWM2OD1zLkCzNVA6KM7:TR?=	NWjHVZJzW0GQR1XS
CAL-54	NUe3OGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjtVVRKSzVyPUGuNFM6PTlizszN	M4jxW3NCVkeHUh?=
DU-145	M4fJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwMEiwO\|Mh\|ryP	MXTTRW5ITVJ?
HCE-4	M3fZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFv0[3JKSzVyPUGuNFkzQDZizszN	M2\EUHNCVkeHUh?=
U-266	M1e2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwMEm2N\|Mh\|ryP	M3;CenNCVkeHUh?=
HT-1197	NWD1U4xpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwMUG0N\|gh\|ryP	MoW4V2FPT0WU
EW-1	NIfoNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoH3TWM2OD1zLkG0NVI5KM7:TR?=	M4Lm[nNCVkeHUh?=
MHH-NB-11	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGH1[oZKSzVyPUGuNVU{PjhizszN	MVTTRW5ITVJ?
NCI-H2405	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTFwMU[xOkDPxE1?	M4SyU3NCVkeHUh?=
COLO-668	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v4eWlEPTB;MT6xOlQ6KM7:TR?=	M1fpc3NCVkeHUh?=
IMR-5	NUe0Rlh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTEOG9XUUN3ME2xMlE3QTN4IN88US=>	MV7TRW5ITVJ?
ARH-77	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXCTWM2OD1zLkKyPVI1KM7:TR?=	NWrS[4dxW0GQR1XS
BHT-101	M1r5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnzRYxKSzVyPUGuNlM1QSEQvF2=	MnXWV2FPT0WU
SCC-25	NWHFcYo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnDbY9KSzVyPUGuNlM2OzZizszN	NF3tenRUSU6JRWK=
NTERA-S-cl-D1	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnWSWZ4UUN3ME2xMlI1OzR4IN88US=>	NVzrdXhWW0GQR1XS
MKN28	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13tVWlEPTB;MT6yOVY{PiEQvF2=	NUO1U4xiW0GQR1XS
KS-1	NVzmWnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTFwMkiyOlkh\|ryP	Mln6V2FPT0WU
NCI-H1734	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULyN3ZjUUN3ME2xMlI5QTF\|IN88US=>	MXzTRW5ITVJ?
ES7	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fMNmlEPTB;MT6yPVU1OiEQvF2=	NV7le5BkW0GQR1XS
NCI-H838	Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTFwM{C2NVUh\|ryP	MXvTRW5ITVJ?
HEC-1	NEHmOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XXNmlEPTB;MT6zN\|c2PSEQvF2=	M2DOdHNCVkeHUh?=
ME-180	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPFb4VVUUN3ME2xMlM4QTl\|IN88US=>	NUPhPII{W0GQR1XS
MMAC-SF	M{Oxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4CyfmlEPTB;MT6zPVU6PSEQvF2=	M3rMVnNCVkeHUh?=
IA-LM	M3e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37mOWlEPTB;MT60NFkyPCEQvF2=	M4nydHNCVkeHUh?=
MN-60	M4Hn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFwNEOxNVQh\|ryP	MWPTRW5ITVJ?
SIMA	M3[4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7EclNKSzVyPUGuOFg3QDdizszN	MUfTRW5ITVJ?
NCI-H1770	NVrQVGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTveGdNUUN3ME2xMlUzODV2IN88US=>	MYfTRW5ITVJ?
ONS-76	NVO3RpdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTwTWM2OD1zLkWyN\|EyKM7:TR?=	MWfTRW5ITVJ?
LB771-HNC	NWDOVphqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2flcmlEPTB;MT61N\|kxPiEQvF2=	M1jLeHNCVkeHUh?=
SW48	NHHNcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M372cWlEPTB;MT61OFI1OyEQvF2=	NIrmbGZUSU6JRWK=
KYSE-140	NXLhVY0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTFwNUW3OFEh\|ryP	M1eyT3NCVkeHUh?=
SW626	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnTTll6UUN3ME2xMlU5OTZizszN	Mne5V2FPT0WU
MC-CAR	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfSTWM2OD1zLkW4OlY{KM7:TR?=	M1LzUHNCVkeHUh?=
D-336MG	M2LuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjYV\|JNUUN3ME2xMlYzQTRizszN	M2W3T3NCVkeHUh?=
SK-MEL-3	M2Dycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrhNYt{UUN3ME2xMlY{QTB{IN88US=>	NXfhbWtsW0GQR1XS
MHH-PREB-1	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrqTWM2OD1zLk[0OFc{KM7:TR?=	M3TxUXNCVkeHUh?=
Calu-1	NEH6[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGi4SmZKSzVyPUGuOlU{QDZizszN	M4q0WnNCVkeHUh?=
HCC1806	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTFwNk[2NVEh\|ryP	M2jJNnNCVkeHUh?=
A101D	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDUe2dXUUN3ME2xMlY3PzhzIN88US=>	MlPkV2FPT0WU
A704	MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3yxTmlEPTB;MT62PFMyOSEQvF2=	M1T0bXNCVkeHUh?=
LB831-BLC	NHvjRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS4cXFKSzVyPUGuOlk5PTRizszN	NGLTd2tUSU6JRWK=
RL95-2	NVz1TXUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi5UIRYUUN3ME2xMlcyPDZ\|IN88US=>	NWXwbFNIW0GQR1XS
RPMI-2650	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvtbIRKSzVyPUGuO\|I4OTlizszN	NGqxWnFUSU6JRWK=
NH-12	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\nTWM2OD1zLkezOFI4KM7:TR?=	NHrldYpUSU6JRWK=
AGS	M13LR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfPOmJKSzVyPUGuO\|Y{PThizszN	NHvybVZUSU6JRWK=
NEC8	NFzTV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7oTWM2OD1zLke4PVk2KM7:TR?=	MmTtV2FPT0WU
NCI-H2009	M3;Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFuydm1KSzVyPUGuO\|k4OjFizszN	Ml\MV2FPT0WU
A498	NIKwOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnm3TWM2OD1zLkixNlgzKM7:TR?=	NWLNe5VLW0GQR1XS
NCI-H810	NUToZVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\pTm1KSzVyPUGuPFE3ODZizszN	MmL2V2FPT0WU
SK-NEP-1	M33CR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf1T3dqUUN3ME2xMlg{PzZ5IN88US=>	NVzOU5UzW0GQR1XS
D-542MG	NVPkdWRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rR[GlEPTB;MT64OVg2OSEQvF2=	M1;JN3NCVkeHUh?=
KNS-42	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTFwOE[yOlYh\|ryP	Mn7jV2FPT0WU
NCI-H2452	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTiRYU1UUN3ME2xMlg6ODd2IN88US=>	Ml\TV2FPT0WU
SK-MEL-2	NGDLS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHK1WmpKSzVyPUGuPVAzPzFizszN	M2nHSHNCVkeHUh?=
OVCAR-5	NGeycpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofwTWM2OD1zLkmwOlc2KM7:TR?=	NWDQ[GdyW0GQR1XS
SNG-M	NWmxNWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LmcmlEPTB;MT65OVg2QCEQvF2=	NH\lUJZUSU6JRWK=
A673	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TBWmlEPTB;MT65O\|UyPiEQvF2=	MmfqV2FPT0WU
L-428	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XpfWlEPTB;MT65PVE4QSEQvF2=	NEXSfVhUSU6JRWK=
KM-H2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\OeW9KSzVyPUKuNFExQSEQvF2=	NIntcXZUSU6JRWK=
MC-IXC	M2f6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTEToQ5UUN3ME2yMlAzOjd\|IN88US=>	M2ixb3NCVkeHUh?=
COLO-678	NWruSoRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTJwMESyNFch\|ryP	NES3[IdUSU6JRWK=
MEL-JUSO	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3njWmlEPTB;Mj6wO\|g2OSEQvF2=	NWHM[ItJW0GQR1XS
HCC38	M3q5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTJwMEi0N\|Mh\|ryP	NH\YUYFUSU6JRWK=
UACC-62	NUHSZldiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ztOWlEPTB;Mj6wPFg2PSEQvF2=	NHjoNZBUSU6JRWK=
OAW-42	M1TpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJwMEm3NVEh\|ryP	MVzTRW5ITVJ?
LB996-RCC	M17TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJwMUO4NVch\|ryP	MUXTRW5ITVJ?
COR-L105	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{WyVWlEPTB;Mj6xOlM4OyEQvF2=	MoCyV2FPT0WU
RCC10RGB	NGnyXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHOzZXpKSzVyPUKuNVg2PzZizszN	NE\5XHpUSU6JRWK=
A431	NHvZV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn1UHhKSzVyPUKuNVkxOTlizszN	NFuzW5ZUSU6JRWK=
NCI-H292	NUDwVlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJwMkO5OVEh\|ryP	NF;tVWpUSU6JRWK=
SK-UT-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PPVGlEPTB;Mj6zN\|E5PCEQvF2=	NFmwWnlUSU6JRWK=
PANC-08-13	NXPYUmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfQR3VKSzVyPUKuN\|MzOzVizszN	MV;TRW5ITVJ?
ST486	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW5TWM2OD1{LkSxNFQ5KM7:TR?=	Mo\FV2FPT0WU
SJSA-1	NW\1b\|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXX5[YlWUUN3ME2yMlQyOjdzIN88US=>	NIL1O3JUSU6JRWK=
RKO	NF:yUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1n2OWlEPTB;Mj60NlAzQSEQvF2=	MnnQV2FPT0WU
NCI-H1793	M1vhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nveWlEPTB;Mj60OFAzQSEQvF2=	M2DWNHNCVkeHUh?=
639-V	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPzTWM2OD1{LkS1N\|gzKM7:TR?=	MWrTRW5ITVJ?
ES3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjI[mlKSzVyPUKuOFk4OzdizszN	MkLvV2FPT0WU
NCI-H1792	NGDOdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDKPFNDUUN3ME2yMlU3QDJ4IN88US=>	NFH4ZpdUSU6JRWK=
NCI-H1651	MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HiRmlEPTB;Mj61PFIyKM7:TR?=	MV7TRW5ITVJ?
SN12C	NHfNNZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3u[4x[UUN3ME2yMlU5PDh5IN88US=>	Mo\RV2FPT0WU
COLO-679	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\XZYZKSzVyPUKuOVg3ODVizszN	Mn3VV2FPT0WU
U-118-MG	MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJwNUi4O\|Ih\|ryP	MYXTRW5ITVJ?
Ramos-2G6-4C10	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPRTWM2OD1{Lk[0PFA4KM7:TR?=	MoPFV2FPT0WU
HCT-15	NED6T4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jXUGlEPTB;Mj62PFc6OiEQvF2=	NIfFTlhUSU6JRWK=
MDA-MB-157	NID1b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXFVFdKSzVyPUKuO\|A4PDdizszN	M1PSOXNCVkeHUh?=
K5	NVOwN4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvycJJKSzVyPUKuO\|E5PDVizszN	NWH1cGlrW0GQR1XS
MKN45	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD0N2E1UUN3ME2yMlc{OzZ4IN88US=>	NXnidHhOW0GQR1XS
DMS-273	NXnrPFhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\4[VBEUUN3ME2yMlc2PjN{IN88US=>	M1\MVHNCVkeHUh?=
C8166	NXPNS4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTJwN{i1NVMh\|ryP	NXnINo5ZW0GQR1XS
Calu-3	M4TyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTJwN{i5Olkh\|ryP	MXvTRW5ITVJ?
SNB75	NFOwRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HO[GlEPTB;Mj64PFU{PSEQvF2=	NXe4SVdDW0GQR1XS
BFTC-905	Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rrcWlEPTB;Mj65NFE6OSEQvF2=	MUXTRW5ITVJ?
C-4-II	M4foUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXe5XZBjUUN3ME2yMlkyOzV\|IN88US=>	NFH0T2hUSU6JRWK=
MS-1	NF3ZUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3qTWM2OD1{Lkm2O\|Y6KM7:TR?=	M1;FeXNCVkeHUh?=
A375	NWLGcIpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTNwMEixPFQh\|ryP	MknrV2FPT0WU
KYSE-70	NGnFblNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzXNnRmUUN3ME2zMlA5QDh{IN88US=>	NFXtTG9USU6JRWK=
KYSE-510	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vjW2lEPTB;Mz6xNFk6PSEQvF2=	M3SwWHNCVkeHUh?=
LN-405	NX7ZT5hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HU[WlEPTB;Mz6xN\|UyQCEQvF2=	NEHtZVZUSU6JRWK=
BOKU	M3LKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPidWFkUUN3ME2zMlE1OjV4IN88US=>	M3LvRnNCVkeHUh?=
TE-10	NWDCT4R2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTNwMUezOlIh\|ryP	NX:5NXVFW0GQR1XS
MKN1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPvTWM2OD1\|LkG4OFg{KM7:TR?=	Mk\0V2FPT0WU
M059J	M4DleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoX0TWM2OD1\|LkKwNVc{KM7:TR?=	M37WdXNCVkeHUh?=
GOTO	NGfWTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjoZ2dFUUN3ME2zMlIzODN7IN88US=>	M2K4dnNCVkeHUh?=
DK-MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTkTWM2OD1\|LkK1PVc3KM7:TR?=	MX7TRW5ITVJ?
NCI-H727	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TqUWlEPTB;Mz6yOlU5KM7:TR?=	MVrTRW5ITVJ?
NB12	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\ITWM2OD1\|LkOzNlI1KM7:TR?=	M{f2TnNCVkeHUh?=
DOK	NX3HXG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTNwM{[xPFYh\|ryP	MXrTRW5ITVJ?
KYSE-410	NHThNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jYR2lEPTB;Mz6zOlI5PyEQvF2=	MlHTV2FPT0WU
AM-38	NWrTOHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPLe2hKSzVyPUOuN\|gxPTFizszN	M2LUN3NCVkeHUh?=
GR-ST	M37FWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHCWYlKSzVyPUOuOFU4OzJizszN	MUDTRW5ITVJ?
D-247MG	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLNd3RKSzVyPUOuOFgzPjNizszN	M{G4bXNCVkeHUh?=
TE-8	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfyfYREUUN3ME2zMlQ6OzN\|IN88US=>	NGjVRmtUSU6JRWK=
LS-411N	M{\5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nEdmlEPTB;Mz60PVY6OiEQvF2=	MXXTRW5ITVJ?
SK-MES-1	M1fIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETKdJlKSzVyPUOuOVY1OzNizszN	NFqxcmJUSU6JRWK=
SF295	NF7wR\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\6c4tqUUN3ME2zMlYyPTV{IN88US=>	NHXsdIJUSU6JRWK=
SK-MEL-30	M3[zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TDTGlEPTB;Mz62OVkzOSEQvF2=	M{XuRXNCVkeHUh?=
LB2241-RCC	NIW0UlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTNwNk[yOkDPxE1?	M3jpdnNCVkeHUh?=
PC-14	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXzTWM2OD1\|Lk[2OFM4KM7:TR?=	NIXETm5USU6JRWK=
EW-7	NYnITIt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTNwNke2PVMh\|ryP	MX\TRW5ITVJ?
NMC-G1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\IeFlRUUN3ME2zMlcyQDN5IN88US=>	NGXtbpFUSU6JRWK=
TE-441-T	MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTNwN{OwNlgh\|ryP	M2rVSnNCVkeHUh?=
NCI-H1618	NGfjOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXq4bVJzUUN3ME2zMlgyQDd3IN88US=>	M4S4VnNCVkeHUh?=
PANC-03-27	NVfVXo9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvLN2FKSzVyPUOuPFE6OTZizszN	M4mxNHNCVkeHUh?=
NCI-H2228	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHzfGpKSzVyPUOuPFMyOjZizszN	NFixfI5USU6JRWK=
CAPAN-1	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLISJlJUUN3ME2zMlg4ODB7IN88US=>	Mlm5V2FPT0WU
KLE	NUD2SFBlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfNWWtHUUN3ME2zMlkxPjdizszN	MoDwV2FPT0WU
Becker	NWPxbnp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHOVY1KSzVyPUOuPVI5PDlizszN	NEfTcphUSU6JRWK=
SK-PN-DW	NEntVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGi1fZRKSzVyPUSuNFc6PzRizszN	MnHPV2FPT0WU
Hs-578-T	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PCcWlEPTB;ND6wPFMxPiEQvF2=	NI\4eFhUSU6JRWK=
RS4-11	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX1TXRKSzVyPUSuNVEzPTVizszN	MVTTRW5ITVJ?
D-502MG	NX\CRWJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{frT2lEPTB;ND6xOlk6PyEQvF2=	NF\kVXpUSU6JRWK=
GI-1	NWDyNG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1T0Z2lEPTB;ND6yPFI6QSEQvF2=	NVzRNpE1W0GQR1XS
NCI-H209	NIraVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWr4R\|g4UUN3ME20MlM{PzhizszN	MlPCV2FPT0WU
SK-OV-3	M4rlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTRwNEixOFkh\|ryP	MmDFV2FPT0WU
LOUCY	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTRwNEi0N\|Ih\|ryP	MV;TRW5ITVJ?
NCI-H69	NYHsfplXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLNRVNKSzVyPUSuOVE4QTNizszN	M2jvW3NCVkeHUh?=
SCC-9	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWK5SHAzUUN3ME20MlU{OTd{IN88US=>	MXnTRW5ITVJ?
NCI-H526	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojoTWM2OD12LkW5Nlk{KM7:TR?=	NXnESIQ1W0GQR1XS
NCI-H2170	NXX6R4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHLUYhVUUN3ME20MlY3PzdzIN88US=>	NHrI[oRUSU6JRWK=
SR	M1XKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVv4PId1UUN3ME20MlcxODR6IN88US=>	NH;yPHpUSU6JRWK=
CMK	NHPPN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XLXWlEPTB;ND63NlExOSEQvF2=	MoK5V2FPT0WU
COLO-829	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfLV45TUUN3ME20Mlc4ODR\|IN88US=>	MmS3V2FPT0WU
HuO-3N1	NWfZU283T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\JboRKSzVyPUSuPFMzQDFizszN	MV3TRW5ITVJ?
5637	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPM[3RRUUN3ME20MlkxPDh5IN88US=>	NV;vZ4t6W0GQR1XS
A253	NICyOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2q1d2lEPTB;ND65O\|cxQCEQvF2=	M2Wzd3NCVkeHUh?=
NB10	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTVwMEe0PVch\|ryP	MWfTRW5ITVJ?
SF539	NEiwTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWGzZYc5UUN3ME21MlA6QTV7IN88US=>	NWrwdWNqW0GQR1XS
HAL-01	NYnYZplIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2naXGlEPTB;NT6xOFY1PSEQvF2=	M2LvXHNCVkeHUh?=
MHH-ES-1	NXroWolwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XZR2lEPTB;NT6xOlkzPSEQvF2=	Mn7HV2FPT0WU
DEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7uWodKSzVyPUWuNlc2QDJizszN	M1;XPXNCVkeHUh?=
NCI-H1299	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfITWM2OD13LkO1NFA4KM7:TR?=	NFPmbZZUSU6JRWK=
ChaGo-K-1	NVz3WoE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlr6TWM2OD13LkO1NVA4KM7:TR?=	MVTTRW5ITVJ?
HMV-II	M1LTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHrUpZEUUN3ME21MlM6PDNizszN	NXryNnp6W0GQR1XS
NB69	NXnLUo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnCSVZKSzVyPUWuN\|k3OzFizszN	MUnTRW5ITVJ?
NCI-H1882	NGPqd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHv0ZohKSzVyPUWuOFM{PjRizszN	MmHoV2FPT0WU
SNU-475	NGrxSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTVwNEexO\|Eh\|ryP	M2W5Z3NCVkeHUh?=
RXF393	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTVwNEi0PVQh\|ryP	NVyzTWh[W0GQR1XS
CAL-51	MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nOcWlEPTB;NT62Nlg2OyEQvF2=	NXjVcXlFW0GQR1XS
SW1573	M4\iW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDI[osxUUN3ME21MlY{PTN2IN88US=>	M1zRcXNCVkeHUh?=
GCT	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUntTJVIUUN3ME21Mlc2QTJ7IN88US=>	Mn7EV2FPT0WU
COR-L88	NXro[WFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPpTWM2OD13Lke2PFQ3KM7:TR?=	NHrLeJdUSU6JRWK=
MDA-MB-134-VI	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnz2TWM2OD13Lki3OVM3KM7:TR?=	Ml:yV2FPT0WU
NB5	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PENWlEPTB;NT65NlQ1KM7:TR?=	MXTTRW5ITVJ?
GMS-10	MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPJTWM2OD13Lkm2PFYyKM7:TR?=	MVvTRW5ITVJ?
CHP-212	NFvsR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHK1TVRKSzVyPU[uOFgzPjdizszN	NVvxNHdjW0GQR1XS
TE-11	NWXaXY0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfi[G5yUUN3ME22MlU2OTh{IN88US=>	M3[xXHNCVkeHUh?=
SW962	M3XjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXy1eIhYUUN3ME22MlY2Pzd2IN88US=>	MoHmV2FPT0WU
MZ2-MEL	MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTZwOEKwNVEh\|ryP	MVrTRW5ITVJ?
C-33-A	M3\ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTZwOUG2PFgh\|ryP	MXXTRW5ITVJ?
IGR-1	NHHTWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUToRVRJUUN3ME22Mlk4QDJ4IN88US=>	NH;sflJUSU6JRWK=
MOLT-4	NHrZdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTBenRLUUN3ME23MlE2PDB4IN88US=>	MlzEV2FPT0WU
NCI-H1650	NXzJT4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuxSIlKSzVyPUeuNlcxPDZizszN	M1jqSnNCVkeHUh?=
AsPC-1	NIq0SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jLXGlEPTB;Nz6yPFYxPSEQvF2=	NU\PeGY5W0GQR1XS
SNU-C2B	NGjCUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3n3eGlEPTB;Nz6yPVU4OSEQvF2=	M3PSVHNCVkeHUh?=
MKN7	NHHZRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nwbmlEPTB;Nz6zO\|I{PSEQvF2=	NU\4V2hiW0GQR1XS
SW620	NGDWdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3XTWM2OD15LkO4NlA2KM7:TR?=	MonnV2FPT0WU
SK-MEL-28	M3fZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvsTWM2OD15LkSwO\|k5KM7:TR?=	MljOV2FPT0WU
TE-6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTycFFZUUN3ME23MlQ1QTB6IN88US=>	NWO1PGd{W0GQR1XS
D-263MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\0fWlEPTB;Nz60OVc3OiEQvF2=	NGGxT4xUSU6JRWK=
NCI-H1355	NVPQZo83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlr3TWM2OD15Lke3NFI6KM7:TR?=	MV7TRW5ITVJ?
DSH1	NFzBSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTdwN{m3OlIh\|ryP	MoPDV2FPT0WU
NCI-H460	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHyO45KSzVyPUiuNFA3QTRizszN	M2m0ZnNCVkeHUh?=
NCI-H1563	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHGxeYhKSzVyPUiuNFc2ODhizszN	MlzEV2FPT0WU
SW948	NInXWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRThwMUC3OFQh\|ryP	M4i3[HNCVkeHUh?=
LK-2	M4TIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT6TWM2OD16LkGyPFM{KM7:TR?=	M1L2XnNCVkeHUh?=
HT-1080	NFL2W\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHTTWM2OD16LkGzNVc2KM7:TR?=	MVjTRW5ITVJ?
NCI-H441	M{LOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRThwMUmzJO69VQ>?	Ml;yV2FPT0WU
HSC-4	NFrKNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPmXphKSzVyPUiuNlg4OiEQvF2=	NFjBdnFUSU6JRWK=
LXF-289	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT6TWM2OD16LkO1PVQ{KM7:TR?=	MmK4V2FPT0WU
MRK-nu-1	NX[3WW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjP[4wyUUN3ME24MlM3OzB2IN88US=>	NVHMSGNJW0GQR1XS
no-11	MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLrTGtxUUN3ME24MlQ4OTN\|IN88US=>	NGfkbXhUSU6JRWK=
SNU-387	NFH0UIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRThwNkOyOFYh\|ryP	NVzPfo9ZW0GQR1XS
Detroit562	NHfkXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7ISYI1UUN3ME24Mlc2PDV3IN88US=>	NF\FUpFUSU6JRWK=
SW954	NWW4TIduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH[1cZNKSzVyPUiuO\|Y5OzJizszN	MUPTRW5ITVJ?
P12-ICHIKAWA	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nXWGlEPTB;OD63PFk1KM7:TR?=	NHrU[GxUSU6JRWK=
TE-9	NVnBeHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjnTWM2OD16LkixNFYzKM7:TR?=	NVvObpFNW0GQR1XS
NB13	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRThwOEO3PVYh\|ryP	M{Pqb3NCVkeHUh?=
BPH-1	M2nVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nBcWlEPTB;OD64OVA5OSEQvF2=	M2XCR3NCVkeHUh?=
KMOE-2	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoS0TWM2OD16Lki3PFkzKM7:TR?=	M1XPfnNCVkeHUh?=
RPMI-8402	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDVcXhKSzVyPUiuPFk6OjZizszN	M4DKWHNCVkeHUh?=
OVCAR-3	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PIPWlEPTB;OD65O\|c{OiEQvF2=	NFHQS3dUSU6JRWK=
NCI-H2196	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRThwOUi2NFYh\|ryP	M4[4bXNCVkeHUh?=
MZ7-mel	NVz5VlVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljLTWM2OD17LkCzOFYh\|ryP	MnjTV2FPT0WU
GP5d	NWP6NG9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTlwME[zNVMh\|ryP	NVXhUXRUW0GQR1XS
NCI-N87	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nJT2lEPTB;OT60OFc{OSEQvF2=	M1LLcXNCVkeHUh?=
EW-16	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfSTWM2OD17LkS0PFQ5KM7:TR?=	MX7TRW5ITVJ?
Calu-6	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDDUYd3UUN3ME25MlQ6PzB\|IN88US=>	MoDwV2FPT0WU
LC4-1	NVP6UIh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPhXmhqUUN3ME25MlYzPTdizszN	M3nBU3NCVkeHUh?=
CCRF-CEM	NHi4RpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTGW2pHUUN3ME25MlY5PzZ4IN88US=>	MXXTRW5ITVJ?
BC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljDTWM2OD17Lke4PVkh\|ryP	M1\lNXNCVkeHUh?=
NCI-SNU-16	NWfjOFF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXUTWM2OD17Lke5OFk2KM7:TR?=	M1HpbnNCVkeHUh?=
NCI-H28	NY\hU5doT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PhW2lEPTB;OT64OFk{OyEQvF2=	MUfTRW5ITVJ?
SBC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTFyLkC3NkDPxE1?	M4LjSHNCVkeHUh?=
TUR	MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFyLkG2OVch\|ryP	NX\pTGx4W0GQR1XS
MDA-MB-231	NUf0[XdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTFyLkKxNVQh\|ryP	Ml7vV2FPT0WU
C3A	M4TKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFyLkOxO\|kh\|ryP	NYmyVHBlW0GQR1XS
SW1990	NY\QVXY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXZ[HdRUUN3ME2xNE4{OjhizszN	MlPXV2FPT0WU
NCI-H1993	M1rZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;pTWM2OD1zMD61Olk{KM7:TR?=	MXPTRW5ITVJ?
SK-CO-1	M3;IdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTWZ453UUN3ME2xNE44PzdizszN	M4ryUXNCVkeHUh?=
OAW-28	NEW4OZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKzSGtKSzVyPUGwMlk5QDhizszN	Mk\rV2FPT0WU
HN	NH2wNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jNZ2lEPTB;MUGuNVE{OSEQvF2=	MXrTRW5ITVJ?
NCI-H1304	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7JNmdKSzVyPUGxMlE2PzZizszN	NGDaSGNUSU6JRWK=
Daoy	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGC0THdKSzVyPUGxMlQ{OzZizszN	NUPkS2M3W0GQR1XS
VA-ES-BJ	M1HkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLDOHZKSzVyPUGxMlcyQTVizszN	MUHTRW5ITVJ?
MCF7	NFH6bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzWPVZKSzVyPUGxMlgyOjZizszN	NUfHR3VDW0GQR1XS
VM-CUB-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfQ[lFCUUN3ME2xNU46ODlzIN88US=>	M4nLRnNCVkeHUh?=
IPC-298	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO3OIhKSzVyPUGxMlk{QDNizszN	MVTTRW5ITVJ?
NCI-H2126	NITvN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTF{LkCyNVgh\|ryP	MWDTRW5ITVJ?
OVCAR-8	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTF{LkGxOFEh\|ryP	MYXTRW5ITVJ?
SJRH30	NILqe\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzaeYZKSzVyPUGyMlIzQTlizszN	M1e3NnNCVkeHUh?=
DMS-53	NHPYc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTF{LkK2OFkh\|ryP	NFXFZoxUSU6JRWK=
NCI-H322M	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vyTmlEPTB;MUKuN\|M2PyEQvF2=	MmD6V2FPT0WU
RVH-421	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH6y[\|FKSzVyPUGyMlQ6ODRizszN	NHfCRYlUSU6JRWK=
Raji	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlW4TWM2OD1zMj62NVQh\|ryP	M3PtXHNCVkeHUh?=
MDA-MB-415	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTF{Lk[0OFQh\|ryP	NGHuW2xUSU6JRWK=
EFE-184	NYjURpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXv2clVOUUN3ME2xNk44OTB4IN88US=>	MnzhV2FPT0WU
BFTC-909	NXK2PWZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXLeGhKSzVyPUGyMlkzPDdizszN	NVLTTphxW0GQR1XS
BHY	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13mUGlEPTB;MUOuN\|M6KM7:TR?=	M{TxUHNCVkeHUh?=
YKG-1	M3PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV30W2JoUUN3ME2xN{4{PzR7IN88US=>	MYnTRW5ITVJ?
EW-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nRR2lEPTB;MUOuO\|E3OyEQvF2=	M3T6dnNCVkeHUh?=
HCC1143	M2rP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfxb5A1UUN3ME2xN{44PDN5IN88US=>	MlrTV2FPT0WU
REH	M2n3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHq[WJKSzVyPUGzMlg6QDJizszN	NIWwcG9USU6JRWK=
CESS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF\|Lkm0PFkh\|ryP	MV;TRW5ITVJ?
EFM-19	NVPtbmZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;kXplXUUN3ME2xOE4yOTF{IN88US=>	MX\TRW5ITVJ?
U031	M1TCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{GxXmlEPTB;MUSuOFA5PSEQvF2=	M2qxTHNCVkeHUh?=
ES1	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTF2LkS4OVEh\|ryP	NYqxTZBkW0GQR1XS
HSC-3	NIm1TW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEWwSFZKSzVyPUG0MlYzOTVizszN	M2q3cnNCVkeHUh?=
LOXIMVI	NFLBe\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LQbGlEPTB;MUSuO\|A3QCEQvF2=	Mmq0V2FPT0WU
A388	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml23TWM2OD1zND63OVU3KM7:TR?=	NE\pU3pUSU6JRWK=
KP-N-YS	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkToTWM2OD1zND63O\|Mh\|ryP	NWfoUldDW0GQR1XS
Capan-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF2Lke4OkDPxE1?	M4HRPHNCVkeHUh?=
SKG-IIIa	NIno[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDyPJdxUUN3ME2xOE45QDZ{IN88US=>	NGjBOYdUSU6JRWK=
HEL	NHLScopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;hUWlEPTB;MUSuPFk6PyEQvF2=	NV;UcpoxW0GQR1XS
BEN	M3z1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnmzTWM2OD1zND65O\|Y3KM7:TR?=	NFjGSINUSU6JRWK=
MC116	NFrT[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DCfGlEPTB;MUWuNVU6QSEQvF2=	M{jHSnNCVkeHUh?=
IGROV-1	NFPHSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL2[Wg6UUN3ME2xOU4zOzF5IN88US=>	M1vze3NCVkeHUh?=
NCI-H1648	M4PzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHoOXV2UUN3ME2xOU42OzB3IN88US=>	M3jKeHNCVkeHUh?=
ABC-1	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2f5XGlEPTB;MUWuPFA{OyEQvF2=	MYfTRW5ITVJ?
EW-18	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[1UFlKSzVyPUG1Mlk6PzlizszN	NFvqUFNUSU6JRWK=
BC-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHPTWM2OD1zNj6wOVYzKM7:TR?=	NI\McFRUSU6JRWK=
NCI-H1437	M1W4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfqTWM2OD1zNj6wOlY4KM7:TR?=	NXfHOVU2W0GQR1XS
SCC-15	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTF4LkK4NlUh\|ryP	M2jtV3NCVkeHUh?=
TT	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrBRllKSzVyPUG2MlU5QDhizszN	M2XFNnNCVkeHUh?=
KINGS-1	MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LITWlEPTB;MU[uPFI4OyEQvF2=	NH6zb4tUSU6JRWK=
C32	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLSWWhGUUN3ME2xOk46PzF5IN88US=>	MmCxV2FPT0WU
SBC-5	NFLES4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fXXGlEPTB;MUeuNVQ4QSEQvF2=	MnfOV2FPT0WU
NB1	NYPKOmt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXXTWM2OD1zNz6zNVg5KM7:TR?=	M3X0VHNCVkeHUh?=
EB-3	NFz6TFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HVcmlEPTB;MUeuOVc3KM7:TR?=	M1PiVXNCVkeHUh?=
NCI-H748	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTtNppuUUN3ME2xO{44ODN3IN88US=>	MonUV2FPT0WU
IST-SL1	NHzP[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fKb2lEPTB;MUeuO\|UzPiEQvF2=	NVjFfpk{W0GQR1XS
WM-115	M3nyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX60UGZoUUN3ME2xO{45ODh3IN88US=>	M1XKXHNCVkeHUh?=
NCI-H226	M4rSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTF5Lkm1OFYh\|ryP	MW\TRW5ITVJ?
CAL-33	NIq5XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofhTWM2OD1zOD6yO\|gyKM7:TR?=	MoTpV2FPT0WU
SCC-4	M{XIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPZelVKSzVyPUG4MlMzOjlizszN	NITXSXRUSU6JRWK=
RMG-I	NUfvWHpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVv1XGZKUUN3ME2xPE43QTR5IN88US=>	M1rVRXNCVkeHUh?=
KOSC-2	NInJU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M372dWlEPTB;MUiuO\|c1PiEQvF2=	NXqyV2FYW0GQR1XS
A2058	NIHkcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTF6LkiyOVUh\|ryP	Mn3MV2FPT0WU
HCC70	NWfReXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTF7LkO4PVQh\|ryP	NHjQRoRUSU6JRWK=
C2BBe1	M3vIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\DTWM2OD1zOT60NVQ5KM7:TR?=	MU\TRW5ITVJ?
NCI-H650	NIHuOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfJNIVNUUN3ME2xPU42QDl7IN88US=>	NFLYb5VUSU6JRWK=
CAL-72	NXf3NINUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTYNWJQUUN3ME2xPU43PzN5IN88US=>	M{HsOHNCVkeHUh?=
L-363	M{ewdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTJyLkCyNVIh\|ryP	MVLTRW5ITVJ?
SNU-423	NXzxTYVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LKTmlEPTB;MkCuNVA1OyEQvF2=	MVTTRW5ITVJ?
PLC-PRF-5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrTd5NKSzVyPUKwMlM6ODZizszN	M3i0UHNCVkeHUh?=
SW1463	MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLtTWM2OD1{MD60OVI2KM7:TR?=	NXXSN25SW0GQR1XS
769-P	NIntcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjYe3VbUUN3ME2yNE43PzZ7IN88US=>	MnPJV2FPT0WU
DMS-79	M3fYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;n[HJKSzVyPUKwMlg1QSEQvF2=	M3L2NHNCVkeHUh?=
Saos-2	NXT2cZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknlTWM2OD1{MD65OVU3KM7:TR?=	MXTTRW5ITVJ?
CHP-126	NYf3V49pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qzWGlEPTB;MkGuOFQ3OiEQvF2=	MoDPV2FPT0WU
SW837	NECxfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTJzLkS5N\|kh\|ryP	M4DwR3NCVkeHUh?=
SHP-77	M1XSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfITWM2OD1{MT62NVIzKM7:TR?=	NUH6N3VZW0GQR1XS
DB	NUnvfo82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3MdWF{UUN3ME2yNU43OTR{IN88US=>	MYPTRW5ITVJ?
ES5	NVPmVHdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjSOWxNUUN3ME2yNU43QDZ2IN88US=>	MYTTRW5ITVJ?
COR-L23	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTJzLkiwOVEh\|ryP	NV7zfJQ6W0GQR1XS
KU-19-19	Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrRN2hKSzVyPUKxMlg6QDJizszN	NUnJOnZCW0GQR1XS
T84	NWXxTHBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvmTWM2OD1{MT65PFE6KM7:TR?=	M3fhb3NCVkeHUh?=
NCI-H630	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PNVmlEPTB;MkKuOVM3OyEQvF2=	M2L2bHNCVkeHUh?=
LU-165	NH64ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTJ{LkW1OEDPxE1?	NWrIRVc2W0GQR1XS
COLO-792	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmq0TWM2OD1{Mj63NVEyKM7:TR?=	MU\TRW5ITVJ?
CAL-62	NF;3XG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzwTWM2OD1{Mj63OVE4KM7:TR?=	MVPTRW5ITVJ?
HCE-T	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmK1TWM2OD1{Mj64OlA3KM7:TR?=	NIW3fXlUSU6JRWK=
BB65-RCC	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fHTWlEPTB;MkOuNFM1PCEQvF2=	M{PqWXNCVkeHUh?=
SiHa	M3Ha[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nYWGlEPTB;MkOuN\|k3QCEQvF2=	M3q0WnNCVkeHUh?=
NCI-H2081	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTJ2LkC2OFEh\|ryP	MVPTRW5ITVJ?
U251	MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTOXHQ1UUN3ME2yOE4xPjZ6IN88US=>	MmX1V2FPT0WU
LoVo	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPOcW1vUUN3ME2yOE46Ojh{IN88US=>	Ml;lV2FPT0WU
GCIY	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF30TpdKSzVyPUK1MlI5PzdizszN	MW\TRW5ITVJ?
NUGC-3	NVfaWXF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTJ3LkOzNVYh\|ryP	MXjTRW5ITVJ?
LNCaP-Clone-FGC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHLZmlJUUN3ME2yOU4{PDl6IN88US=>	MkDpV2FPT0WU
PA-1	M{\QZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NES0WYxKSzVyPUK1MlY5OzNizszN	MkH6V2FPT0WU
OE33	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ3Lk[4OVMh\|ryP	MU\TRW5ITVJ?
HT-29	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJ3Lke4O\|kh\|ryP	NE\xeJNUSU6JRWK=
RCM-1	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jiN2lEPTB;MkWuPVY2PiEQvF2=	MmTDV2FPT0WU
NCI-H1522	M4G3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2GzU2lEPTB;MkWuPVkyOSEQvF2=	MmDFV2FPT0WU
LB373-MEL-D	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF25bmRKSzVyPUK2MlE4ODhizszN	NYfkVodoW0GQR1XS
NCI-H1436	M{nyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXkTWM2OD1{Nj6yO\|M5KM7:TR?=	NGnybXhUSU6JRWK=
COLO-824	NXTXbG1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjDeHQ6UUN3ME2yOk41ODB{IN88US=>	MlW2V2FPT0WU
CP50-MEL-B	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnUTWM2OD1{Nj61Olc2KM7:TR?=	MnrrV2FPT0WU
EGI-1	NFz4U3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPxSolKSzVyPUK3MlI3QThizszN	NHjnUZhUSU6JRWK=
LAN-6	M1T4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJ5LkO1PVgh\|ryP	MnHPV2FPT0WU
GAK	NIXvTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXHTXNKSzVyPUK3MlQzOjVizszN	NGXTOlVUSU6JRWK=
MDA-MB-175-VII	NFrVR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDaUplKSzVyPUK3MlUxPTNizszN	NW\vSpNpW0GQR1XS
JVM-2	NUW0Sm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7oToQzUUN3ME2yO{43PjJ{IN88US=>	Ml3LV2FPT0WU
UACC-257	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTJ5Lk[4O\|gh\|ryP	M33WcHNCVkeHUh?=
SW1783	NVXocZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDzOZpKSzVyPUK3Mlc4QDNizszN	MUXTRW5ITVJ?
HT-3	NHm1S5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmntTWM2OD1{OD6yNVY3KM7:TR?=	M33udHNCVkeHUh?=
RL	M4TIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTJ6LkW5NVEh\|ryP	NITWcWFUSU6JRWK=
TK10	NETUN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSy[mJKSzVyPUK4MlY2OzVizszN	Mn3vV2FPT0WU
HT55	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;2NIJqUUN3ME2yPU4xPTZ3IN88US=>	NEDRVY1USU6JRWK=
BT-20	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfofpZWUUN3ME2yPU4xPTh4IN88US=>	NF7mXnBUSU6JRWK=
TGBC24TKB	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDLTWM2OD1{OT6xPFMyKM7:TR?=	NEC0NWFUSU6JRWK=
HSC-2	M{Laemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX75R4NVUUN3ME2yPU4{ODBzIN88US=>	Mlr4V2FPT0WU
COLO-205	NXn0VGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTJ7LkO5OFQh\|ryP	NXnGS5J1W0GQR1XS
GT3TKB	M{jUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fWPGlEPTB;MkmuOlg4PyEQvF2=	NWfRcog2W0GQR1XS
T47D	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTJ7Lki1PFIh\|ryP	MXjTRW5ITVJ?
OMC-1	M4exVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnkTWM2OD1\|MD6xPVE6KM7:TR?=	Mlr6V2FPT0WU
PFSK-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTNzLkK2OVkh\|ryP	MXzTRW5ITVJ?
JEG-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnq[odKSzVyPUOxMlM2PjFizszN	M{nRUXNCVkeHUh?=
RD	M3L1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfmZ2VKSzVyPUOxMlUyOTVizszN	NV;5XplXW0GQR1XS
NCI-H64	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TOOmlEPTB;M{KuOFE4QSEQvF2=	NEK4XlNUSU6JRWK=
DMS-114	NEHBNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37wUGlEPTB;M{KuOFE5OiEQvF2=	MkfLV2FPT0WU
NCI-H661	MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LqcmlEPTB;M{KuOlUxOSEQvF2=	MmfCV2FPT0WU
CAL-148	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:zPXZiUUN3ME2zNk43PjZ3IN88US=>	MmPQV2FPT0WU
HuP-T3	NVO4SXlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTN{LkmzN\|gh\|ryP	NEHQUG9USU6JRWK=
ES4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHUTWM2OD1\|Mz6xO\|A2KM7:TR?=	NUexUZVlW0GQR1XS
Ca9-22	NITHdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUn3O4tWUUN3ME2zN{41PjBzIN88US=>	MX;TRW5ITVJ?
LP-1	M1PO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\WTWM2OD1\|ND6wPUDPxE1?	MWTTRW5ITVJ?
AU565	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHviUZdKSzVyPUO0MlUxPjlizszN	Mkn3V2FPT0WU
MDA-MB-453	M4TRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTN3LkG0NlYh\|ryP	NE\iVYZUSU6JRWK=
SNU-C1	NXPhRWlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\OTWM2OD1\|NT6xO\|Eh\|ryP	NFe4d\|dUSU6JRWK=
SW13	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTJXXVbUUN3ME2zOU41ODd4IN88US=>	NWC1RlQxW0GQR1XS
NCI-H2122	NXTINoVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXofWRKSzVyPUO1MlU2QThizszN	NFnaWlJUSU6JRWK=
NCI-H1395	NVvpfZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTN3Lk[2PVEh\|ryP	MXTTRW5ITVJ?
J-RT3-T3-5	NFXi[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7OTWM2OD1\|Nj6wNlk1KM7:TR?=	NFzqUZlUSU6JRWK=
COR-L279	M2npZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTN4LkG5PFEh\|ryP	NXTRWZZrW0GQR1XS
ATN-1	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jsdmlEPTB;M{[uPFUyPiEQvF2=	MmXTV2FPT0WU
HCC2998	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofuTWM2OD1\|Nj64OVcyKM7:TR?=	M4TWbnNCVkeHUh?=
UM-UC-3	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\KbmlEPTB;M{[uPFY4PSEQvF2=	M{nzbXNCVkeHUh?=
DV-90	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTN4LkmwOlch\|ryP	M2rsUHNCVkeHUh?=
ES8	MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnqZ3FKSzVyPUO2Mlk{OThizszN	MkfZV2FPT0WU
YAPC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7tTWM2OD1\|Nj65OlU1KM7:TR?=	NFqzeFZUSU6JRWK=
HCC1599	M3LEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfwTWM2OD1\|Nz6xOlE5KM7:TR?=	NGfUPWlUSU6JRWK=
UMC-11	NVHQeZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLUTWM2OD1\|Nz6yOVA{KM7:TR?=	NGDDTpRUSU6JRWK=
THP-1	NWr6cotIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTN5LkK4Olgh\|ryP	NXLxOHVbW0GQR1XS
OCUB-M	M{i3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvLb5pKSzVyPUO3MlI5QTFizszN	MVLTRW5ITVJ?
NCI-H1693	MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLQUI9KSzVyPUO3MlMzOzNizszN	MnG1V2FPT0WU
NCI-H345	NHHjdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkn4TWM2OD1\|Nz6zOlI1KM7:TR?=	M3P5TXNCVkeHUh?=
COLO-800	NYnvRpQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHJTWM2OD1\|Nz61Olch\|ryP	Mn;6V2FPT0WU
COLO-320-HSR	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrjO4ZKSzVyPUO4MlM1QTJizszN	MmPCV2FPT0WU
NCI-H596	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDB[GVKSzVyPUO4MlQ1QDlizszN	NEjSRYhUSU6JRWK=
NCI-H187	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP1TWM2OD1\|OD63N\|Q1KM7:TR?=	NX2zUJpxW0GQR1XS
ECC4	NUW0NXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTN7LkC4NVQh\|ryP	M{D2VXNCVkeHUh?=
KP-4	NFjJem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LsdWlEPTB;M{muNVI{PSEQvF2=	NU[3Xow3W0GQR1XS
NCI-H2227	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDEeZhKSzVyPUO5MlM6PDlizszN	MWnTRW5ITVJ?
22RV1	NFv4SVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF:xb\|ZKSzVyPUO5Mlg{QThizszN	MV3TRW5ITVJ?
SAS	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPSe3dbUUN3ME20NE4xQTZizszN	NXvndYFQW0GQR1XS
PANC-10-05	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUey[3FKUUN3ME20NE4yQDJ6IN88US=>	NGH5TWZUSU6JRWK=
MDA-MB-468	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULHNHZ[UUN3ME20NE42OzR4IN88US=>	MkH6V2FPT0WU
RPMI-7951	NX3yN4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvuTWM2OD12MT6yNFc2KM7:TR?=	NXK2fXkyW0GQR1XS
BB49-HNC	M3rXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Ww[GlEPTB;NEGuNlE4QSEQvF2=	MojQV2FPT0WU
23132-87	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnmWYp5UUN3ME20NU4zPzN{IN88US=>	M3LVWnNCVkeHUh?=
HCC1569	M1fEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP1TWM2OD12MT6yPFg2KM7:TR?=	NHrDRVhUSU6JRWK=
CP66-MEL	Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TndmlEPTB;NEKuNVg5PiEQvF2=	NHzXd2RUSU6JRWK=
K-562	M{\jdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4G1VGlEPTB;NEKuNlg2PCEQvF2=	NV3VZVZrW0GQR1XS
OCI-AML2	NGLYdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTR{Lki5O\|Qh\|ryP	NWjpZ2I{W0GQR1XS
SW756	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HTOWlEPTB;NEOuNFM5QCEQvF2=	M1XhVXNCVkeHUh?=
M14	NHWzeYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTR\|LkOxPFkh\|ryP	NEDG[IlUSU6JRWK=
NCI-H1623	M2n5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlftTWM2OD12Mz60OlQh\|ryP	MkW4V2FPT0WU
KNS-81-FD	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjYRohKSzVyPUSzMlc3OiEQvF2=	NG\TS\|FUSU6JRWK=
TGBC1TKB	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjRUpBKSzVyPUSzMlkxQTlizszN	NEC2OWJUSU6JRWK=
RERF-LC-MS	NVTpcIJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj0eGVKSzVyPUSzMlkzQDFizszN	NGHvR2lUSU6JRWK=
PC-3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTR2LkSzOFch\|ryP	MYXTRW5ITVJ?
HuP-T4	M3nsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTR2LkS0O\|Qh\|ryP	MVTTRW5ITVJ?
NCI-H510A	M{\wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTR2LkewPEDPxE1?	MWnTRW5ITVJ?
LB2518-MEL	NEHYV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTR2Lke5N\|ch\|ryP	NEXrW2dUSU6JRWK=
TE-5	NXLuPVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXJTWM2OD12NT65OVgyKM7:TR?=	MXjTRW5ITVJ?
EW-24	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTR4LkG3NlMh\|ryP	MoPqV2FPT0WU
LB647-SCLC	NGS2PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfuTJdKSzVyPUS2MlIyPTVizszN	NG\wRndUSU6JRWK=
NCI-H524	NFXhfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTR4LkexPFUh\|ryP	NX62WoJLW0GQR1XS
EW-11	NW\IfW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTR4LkmzO\|Mh\|ryP	MXzTRW5ITVJ?
KALS-1	NVrx[FBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTR5LkKwOlYh\|ryP	MYTTRW5ITVJ?
BT-474	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj5To1VUUN3ME20O{41OjF4IN88US=>	MUTTRW5ITVJ?
SK-N-AS	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPjTWM2OD12Nz64PFgh\|ryP	NHnifWlUSU6JRWK=
HCC2157	M2jMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTR6LkC3OkDPxE1?	M3vifnNCVkeHUh?=
HCC1954	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTR6LkG3NFQh\|ryP	MlzjV2FPT0WU
FADU	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHKTWM2OD12OD6zNFMyKM7:TR?=	MYXTRW5ITVJ?
S-117	NFz6W\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTR6LkO4NVUh\|ryP	MVHTRW5ITVJ?
LS-1034	NV3pdmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nSVGlEPTB;NEiuO\|A3PyEQvF2=	NF7iO2VUSU6JRWK=
CAMA-1	NYTtcFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\mT5NKSzVyPUS5MlU2PDNizszN	MWfTRW5ITVJ?
LU-134-A	NXXFVW91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjKbXRKSzVyPUS5MlgxQDVizszN	NUHGVWRDW0GQR1XS
NCI-H1838	NWfle\|NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{H2dmlEPTB;NEmuPFA5PyEQvF2=	NFHtemtUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	- Collapse Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN1CCN(CC1)CC2=C(C=C(NC(=O)C3=CC(=C(C)C=C3)C#CC4=CN=C5C=CC=N[N]45)C=C2)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	November 22 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib Mesylate (STI571) induces autophagy.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)